Loratadine
- Generic Name
- Loratadine
- Brand Names
- Alavert, Alavert D, Allerclear, Claritin, Claritin-D, Diphen, Loradamed, Wal-itin, Wal-itin D
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23ClN2O2
- CAS Number
- 79794-75-5
- Unique Ingredient Identifier
- 7AJO3BO7QN
- Background
Loratadine is a second generation antihistamine used to manage symptoms of allergic rhinitis. A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations.
- Indication
Loratadine is a 2nd generation antihistamine and is used to manage symptoms of allergic rhinitis, wheal formation, urticaria, and other allergic dermatologic conditions.
- Associated Conditions
- Allergic Dermatologic Disorders, Allergic Reaction, Allergic Rhinitis (AR), Allergy to Tree Pollen, Chronic Urticaria, Common Cold, Epiphora, Eye pruritus, Fever, Nasal Congestion, Nasal Itching, Pain, Perennial Allergic Rhinitis (PAR), Pruritus, Rhinitis Perennial, Rhinorrhoea, Seasonal Allergic Rhinitis, Sneezing, Sensation of burning in the eyes, Watery itchy eyes
Combined Antihistaminics Therapy in COVID 19 Patients
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 214
- Registration Number
- NCT05043350
- Locations
- 🇪🇬
Nasr City Insurance Hospital, Cairo, Egypt
Antihistamines in Eosinophilic Esophagitis
- Conditions
- Eosinophilic Esophagitis
- Interventions
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 1
- Registration Number
- NCT04248712
- Locations
- 🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization
- Conditions
- Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 70
- Registration Number
- NCT04211259
- Locations
- 🇺🇸
RWJBarnabas Health - Robert Wood Johnson University Hospital, New Brunswick, New Brunswick, New Jersey, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
A Study to Evaluate Cooling Sensation of an Allergy Product in Adults With a History of Allergies
- First Posted Date
- 2019-11-14
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 468
- Registration Number
- NCT04162795
- Locations
- 🇺🇸
Focus Pointe Global, Teaneck, New Jersey, United States
Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 3
- Registration Number
- NCT03883386
- Locations
- 🇺🇸
The University of Michigan, Ann Arbor, Michigan, United States
Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145)
- Conditions
- Rhinitis, Allergic
- Interventions
- Drug: Placebo tabletDrug: Placebo nasal spray
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 704
- Registration Number
- NCT03855228
Efficacy and Adverse Effects of Prapchompoothaweep Remedy and Loratadine for Treatment in AR Patients
- Conditions
- Adverse Drug EventAllergic RhinitisQuality of Life
- Interventions
- First Posted Date
- 2018-08-21
- Last Posted Date
- 2018-08-22
- Lead Sponsor
- Thammasat University
- Target Recruit Count
- 72
- Registration Number
- NCT03640273
- Locations
- 🇹🇭
Thammasat University, Khlong Luang, Pathumthani, Thailand
A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects
- Conditions
- Clinical Pharmacology
- Interventions
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 52
- Registration Number
- NCT03517930
- Locations
- 🇺🇸
Frontage Clinical Services, Secaucus, New Jersey, United States
A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufactuers Under Fed Conditions in Healthy Adult Subjects
- Conditions
- Clinical Pharmacology
- Interventions
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 29
- Registration Number
- NCT03517943
- Locations
- 🇺🇸
Frontage Clinical Services, Secaucus, New Jersey, United States
A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure
- Conditions
- Rhinitis, Allergic
- Interventions
- Drug: Placebo tabletDrug: Placebo spray
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2019-12-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 82
- Registration Number
- NCT03443843
- Locations
- 🇨🇦
Kingston General Hospital, Kingston, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.